BCL2L11 and lung carcinoma: Ng and colleagues identified a common polymorphism in BIM, a pro-apoptotic protein, as a mediator of intrinsic targeted inhibitor resistance in EGFR-driven lung cancer and chronic myeloid leukemia.54 Normally, MAP kinase pathway signaling activated by the driver oncogene suppresses BIM and it’s pro-apoptotic function.